Abstract
Fifty-six patients out of a group of 99 with lung cancer received postoperative intrapleural BCG (Pasteur strain) in three different dosages (16 X 10(6) culturable particles (cp), 32 X 10(6) cp, and 64 X 10(6) cp). When comparing the whole group of 99 patients with a historical control group of 126 patients no statistically significant differences were found in survival and disease-free interval. The two groups were well matched in respect of age, sex, histology, stage of disease, and type of operation. Patients with epidermoid carcinoma stage I receiving BCG, however, did significantly worse than those who had not received BCG in terms of disease-free interval. This unfavourable trend was caused by earlier local recurrences rather than metastases. The possible phenomenon of enhanced tumour growth noted in or patients with epidermoid carcinoma stage I might be related to the dosages used in this study, but the different BCG strain used hinders comparison with other studies. We conclude that BCG has no beneficial effect on survival or on disease-free interval; possible enhancement of tumour growth in stage I epidermoid carcinoma was found.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bast R. C., Jr, Zbar B., Borsos T., Rapp H. J. BCG and cancer (first of two parts). N Engl J Med. 1974 Jun 20;290(25):1413–1420. doi: 10.1056/NEJM197406202902506. [DOI] [PubMed] [Google Scholar]
- Edwards F. R. Use of BCG as an immunostimulant after resection of carcinoma of the lung: a two-year assessment of a trial of 500 patients. Thorax. 1979 Dec;34(6):801–806. doi: 10.1136/thx.34.6.801. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Jansen H. M., The T. H., Orie N. G. Adjuvant immunotherapy with BCG in squamous cell bronchial carcinoma. Thorax. 1980 Oct;35(10):781–787. doi: 10.1136/thx.35.10.781. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Jansen H. M., The T. H., de Gast G. C., Esselink M. T., van der Wal A. M., Orie N. G. Adjuvant immunotherapy with BCG in squamous-cell bronchial carcinoma. Immune-reactivity in relation to immunostimulation (preliminary results in a controlled trial). Thorax. 1978 Aug;33(4):429–438. doi: 10.1136/thx.33.4.429. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lowe J., Iles P. B., Shore D. F., Langman M. J., Baldwin R. W. Intrapleural BCG in operable lung cancer. Lancet. 1980 Jan 5;1(8158):11–14. doi: 10.1016/s0140-6736(80)90551-6. [DOI] [PubMed] [Google Scholar]
- McKneally M. F., Maver C. M., Kausel H. W. Intrapleural B.C.G. immunostimulation in lung cancer. Lancet. 1977 May 7;1(8019):1003–1003. doi: 10.1016/s0140-6736(77)92299-1. [DOI] [PubMed] [Google Scholar]
- McKneally M. F., Maver C., Kausel H. W., Alley R. D. Regional immunotherapy with intrapleural BCG for lung cancer. J Thorac Cardiovasc Surg. 1976 Sep;72(3):333–338. [PubMed] [Google Scholar]
- Peto R., Pike M. C., Armitage P., Breslow N. E., Cox D. R., Howard S. V., Mantel N., McPherson K., Peto J., Smith P. G. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer. 1977 Jan;35(1):1–39. doi: 10.1038/bjc.1977.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ruckdeschel J. C., Codish S. D., Stranahan A., McKneally M. F. Postoperative empyema improves survival in lung cancer. Documentation and analysis of a natural experiment. N Engl J Med. 1972 Nov 16;287(20):1013–1017. doi: 10.1056/NEJM197211162872004. [DOI] [PubMed] [Google Scholar]
- Sirks J. L., Ruitenberg E. J. Proposals for quality control methods of bacterial vaccines for immunostimulation. I. General considerations. Dev Biol Stand. 1977 Apr 13;38:87–89. [PubMed] [Google Scholar]
- Takita H. Effect of postoperative empyema on survival of patients with bronchogenic carcinoma. J Thorac Cardiovasc Surg. 1970 May;59(5):642–644. [PubMed] [Google Scholar]